Rafael Soria, MD
Family Medicine · Turlock, CANPI 1336147040
Payments from drug & device makers
Across 91 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$404
- Pfizer$226
- Amgen$141
- Lilly USA, LLC$139
- Johnson & Johnson$119
- Boehringer Ingelheim$110
- plus $570 from 18 others
What the payments were for
- Food & beverage$1,69299%
- Education$171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $404 |
| Pfizer | 14 | $226 |
| Amgen | 7 | $141 |
| Lilly USA, LLC | 8 | $139 |
| Johnson & Johnson | 7 | $119 |
| Boehringer Ingelheim | 6 | $110 |
| Novo Nordisk | 4 | $85 |
| Bayer | 3 | $63 |
| Hologic Sales And Service, LLC | 2 | $42 |
| Viatris Specialty LLC | 1 | $42 |
| AbbVie(2 entities) | 2 | $35 |
| Novartis | 2 | $34 |
| Exact Sciences | 1 | $34 |
| Boston Scientific | 1 | $32 |
| Merck | 2 | $31 |
| Abiomed | 1 | $24 |
| Abbott | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 2 | $22 |
| Lundbeck LLC | 1 | $22 |
| Corcept Therapeutics | 1 | $17 |
| GSK | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $13 |
How this compares
$1,710 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 179 | $180,208 |
| EliquisApixaban | 132 | $104,470 |
| JardianceEmpagliflozin | 64 | $70,089 |
| XareltoRivaroxaban | 62 | $59,787 |
| JanuviaSitagliptin Phosphate | 37 | $56,108 |
| FarxigaDapagliflozin Propanediol | 35 | $32,226 |
| RybelsusSemaglutide | 16 | $22,079 |
| TrulicityDulaglutide | 13 | $20,724 |
| Atorvastatin Calcium | 1,129 | $19,356 |
| MounjaroTirzepatide | 18 | $17,982 |
| TradjentaLinagliptin | 24 | $15,407 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $8,663 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $7,912 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $7,888 |
| Spiriva RespimatTiotropium Bromide | 15 | $7,861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $85 | $202,286195 claims |
| PfizerEliquis, Premarin | $226 | $109,017143 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $110 | $93,357103 claims |
| Johnson & JohnsonXarelto | $119 | $59,78762 claims |
| MerckJanuvia | $31 | $56,10837 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humulin N | $139 | $41,52158 claims |
| AstraZenecaFarxiga | $404 | $32,22635 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $15 | $23,70958 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.
Other family medicine in Turlock
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.